Juvenile idiopathic arthritis (systemic) (NICE TA302)
NICE TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis because no evidence submission was received from the manufacturer of the technology.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria